Hypermethylation-mediated silencing of p14 ARF in fibroblasts from idiopathic pulmonary fibrosis

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 303, Issue 4, 2012, Pages

  Cisneros, José ^a   Hagood, James ^b   Checa, Marco ^a   Ortiz Quintero, Blanca ^a   Negreros, Miguel ^a   Herrera, Iliana ^c   Ramos, Carlos ^a   Pardo, Annie ^c   Selman, Moisés ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Apoptosis; Epigenetic; Lung fibrosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; LIPOCORTIN 5; METHYL CPG BINDING PROTEIN; S NITROSOGLUTATHIONE; SMALL INTERFERING RNA; STAUROSPORINE; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA METABOLISM; DNA METHYLATION; EPIGENETICS; FIBROSING ALVEOLITIS; GENE SILENCING; HUMAN; HUMAN CELL; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE; DNA METHYLATION; FIBROBLASTS; GENE SILENCING; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865147542     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00332.2011     Document Type: Article

References (31)

1. Badal V, Menendez S, Coomber D, Lane DP. Regulation of the p14ARF promoter by DNA methylation. Cell Cycle 7: 112-119, 2008.
2. Charles Sherr J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60: 3689-3695, 2000.
3. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol 29: 4325-4339, 2009.
4. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG. Hypermethylation-associated inactivation of p14ARF is independent of p16INK4a methylation and p53 mutational status. Cancer Res 60: 129-133, 2000.
5. Eymin B, Karayan L, Séité P, Brambilla C, Brambilla E, Larsen CJ, Gazzéri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 20: 1033-1041, 2001.
6. Hemmati PG, Normand G, Gillissen B, Wendt J, Dörken B, Daniel PT. Cooperative effect of p21Cip1/WAF-1 and 14-3-3sigma on cell cycle arrest and apoptosis induction by p14ARF. Oncogene 27: 6707-6719, 2008.
7. Horowitz JC, Rogers DS, Sharma V, Vittal R, White ES, Cui Z, Thannickal VJ. Combinatorial activation of Fak and Akt by transforming growth factor-beta1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal 19: 761-771, 2007.
8. Ishida E, Nakamura M, Ikuta M, Shimada K, Matsuyoshi S, Kirita T, Konishi N. Promotor hypermethylation of p14ARF is a key alteration for progression of oral squamous cell carcinoma. Oral Oncol 41: 614-622, 2005.
9. Katzenstein AL, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol 39: 1275-1294, 2008.
10. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 378: 1949-1961, 2011.
11. Kis K, Liu X, Hagood JS. Myofibroblast differentiation and survival in fibrotic disease. Expert Rev Mol Med 13: e27, 2011.
12. Kulasekaren P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ, Horowitz JC. Endothelin-1 and TGF-beta independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol 41: 484-493, 2009.
13. Kuwano K, Hagimoto N, Maeyama T, Fujita M, Yoshimi M, Inoshima I, Nakashima N, Hamada N, Watanabe K, Hara N. Mitochondriamediated apoptosis of lung epithelial cells in idiopathic interstitial pneumonias. Lab Invest 82: 1695-1706, 2002.
14. Lappi-Blanco E, Soini Y, Paakko P. Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 177: 367-376, 1999.
15. Lu Q, Qiu X, Hu N, Wen H, Su Y, Richardson BC. Epigenetics, disease, and therapeutic interventions. Ageing Res Rev 5: 449-467, 2006.
16. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, Kleihues P, Ohgaki H. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11: 159-168, 2001.
17. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220-228, 2010.
18. Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, Gronchi A, Colecchia M, Pierotti MA, Pilotti S. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin Cancer Res 9: 4132-4138, 2003.
19. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT. Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.
20. Ramos C, Montaño M, García-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 24: 591-598, 2001.
21. Ramos C, Montaño M, Becerril C, Cisneros-Lira J, Barrera L, Ruíz V, Pardo A, Selman M. Acidic fibroblast growth factor decreases α-smooth muscle actin expression and induces apoptosis in human normal lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 291: L871-L879, 2006.
22. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, Hagood JS. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol 39: 610-618, 2008.
23. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134: 136-151, 2001.
24. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 12: 2984-2991, 1998.
25. Sherr CJ, Bertwistle D, Besten W DEN, Kuo ML, Sugimoto M, Tago K, Williams RT, Zindy F, Roussel MF. p53-Dependent and-independent functions of the Arf tumor suppressor. Cold Spring Harb Symp Quant Biol 70: 129-37, 2005.
26. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673, 2006.
27. Terasaki Y, Akuta T, Terasaki M, Sawa T, Mori T, Okamoto T, Ozaki M, Takeya M, Akaike T. Guanine nitration in idiopathic pulmonary fibrosis and its implication for carcinogenesis. Am J Respir Crit Care Med 174: 665-673, 2006.
28. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3: 350-356, 2006.
29. White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW, Hogaboam CM, Flaherty KR, Martinez FJ, Kontos CD, Toews GB. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med 173: 112-121, 2006.
30. Xia H, Diebold D, Nho R, Perlman D, Kleidon J, Kahm J, Avdulov S, Peterson M, Nerva J, Bitterman P, Henke C. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med 205: 1659-1672, 2008.
31. Zeini M, Través PG, López-Fontal R, Pantoja C, Matheu A, Serrano M, Boscá L, Hortelano S. Specific contribution of p19(ARF) to nitric oxide-dependent apoptosis. J Immunol 177: 3327-3336, 2006.